SCHEMBL21652918

SCHEMBL21652918

O=C(Nc1cc(F)c(=O)n(CC(F)F)c1)c1cc(Cl)c(Cl)s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 1/20 0.36
▸ DAO P14920 1/20 0.35
▸ MET P08581 1/20 0.35
▸ AXL P30530 1/20 0.35
▸ MAPT P10636 8/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ KMT2A Q03164 4/20 0.33
▸ TP53 P04637 1/20 0.32
▸ RAB9A P51151 4/20 0.32
▸ HTT P42858 2/20 0.32
▸ SHMT2 P34897 1/20 0.31
▸ NPC1 O15118 3/20 0.31
▸ LMNA P02545 2/20 0.31
▸ MAOA P21397 1/20 0.31
▸ MAOB P27338 1/20 0.31
▸ MEN1 O00255 3/20 0.31
▸ CTDSP1 Q9GZU7 2/20 0.31
▸ ENPP2 Q13822 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21653248 0.89 MET (0.34) METAXLMAPTMAPK1KMT2A
SCHEMBL21653156 0.87 PDE10A (0.38) GSK3BDAOMAPTMAPK1KMT2A
SCHEMBL21633837 0.87 MAPT (0.39) METAXLMAPTMAPK1KMT2A
SCHEMBL21653164 0.86 MAPT (0.37) GSK3BDAOMAPTMAPK1KMT2A
SCHEMBL21653057 0.86 MAPT (0.37) METAXLMAPTMAPK1KMT2A
SCHEMBL21653062 0.86 MAPT (0.32) METAXLMAPTMAPK1KMT2A
SCHEMBL21653146 0.86 MET (0.33) METAXLMAPTMAPK1KMT2A
SCHEMBL21653264 0.85 MAPT (0.36) GSK3BDAOMAPTMAPK1KMT2A
SCHEMBL21653010 0.85 MEN1 (0.32) METAXLMAPTMAPK1KMT2A
SCHEMBL21653113 0.84 ALDH1A1 (0.38) GSK3BDAOMAPTMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020023657-A1 PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS Epizyme, Inc. (US) 2020-01-30 — — WO disclosed
Send feedback